UNSPSC 51372308: Ocfentanil

This classification denotes an opioid receptor agonist with the molecular formula C22H27FN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MX52WBC8EV, chemically known as acetamide, n-(2-fluorophenyl)-2-methoxy-n-(1-(2-phenylethyl)-4-piperidinyl)- but generally known as ocfentanil, which bears US NIH Compound Identifier 60575. European Medicines Agency schedules Ocfentanil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09396MIG.

UNSPSC 51372308 Ocfentanil is a Commodity code that encompasses pharmaceutical products and controlled substances acquired by state and local governments, though recent opportunities tagged under this code show significant scope mismatch — the posted solicitations address naloxone (an opioid antagonist), generic pharmaceuticals, and pharmacy benefit management programs rather than ocfentanil specifically. State and local issuing bodies acquiring under this code include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions. The work being solicited ranges from direct procurement of naloxone and drug deactivation systems for community health initiatives to broader pharmaceutical supply agreements covering generic multi-source drugs and OTC products distributed through authorized wholesalers and state pharmacy benefit programs.

Recent activity centers in Florida and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023 (note: the deadline date in the source appears inconsistent with the posting date). The Minnesota Department of Administration's Office of State Procurement, on behalf of the Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs without a formal competitive deadline. Cooperative purchasing vehicles, particularly MMCAP, play a significant role in this market, enabling state and local entities to aggregate demand across multiple jurisdictions. Vendors must typically comply with FDA requirements, Drug Supply Chain Security Act (DSCSA) certification, current Good Manufacturing Practices (cGMP), E-Verify employment verification, drug-free workplace certification, and specified insurance coverages including commercial general liability ranging to $5,000,000 per occurrence.